The nuclear factor I (NFI) family of transcription factors comprises four members in humans, NFIA, NFIB, NFIC and NFIX, which are involved in various cellular processes. 1 The NFI proteins comprise a DNA binding and dimerization domain in their N-terminal half, which contains four cysteine residues common to the four vertebrate members and conserved in the nonvertebrate orthologs, and a transactivation and repression domain in their C-terminal half (Figure 1a) . The NFIA gene, located in the 1p31 chromosomal region, has a function in brain, [2] [3] [4] ureteral and renal development 3 as well as hematopoiesis. 5, 6 Interactions of NFIA with CEBPa and PU.1 through microRNAs regulate granulocytic and monocytic differentiation, respectively. 5, 6 NFIA regulates erythropoiesis through a network involving NR2C1, GATA1 and erythropoietin. [7] [8] [9] To determine whether NFIA could have a function in early leukemogenesis, we searched for alterations of the NFIA gene in 89 chronic hematopoietic diseases by using array-comparative genomic hybridization (aCGH) and DNA sequencing. Our series comprised 35 chronic myelomonocytic leukemias and 54 myeloproliferative disorders including 8 cases of polycythemia vera (PV), 42 cases of essential thrombocythemia and 4 cases of idiopathic myelofibrosis. The aCGH experiments used high-density oligonucleotide microarrays (Hu-244A, Agilent Technologies, Massy, France) as previously described. 10 aCGH was done on 84 samples. We sequenced exons 2-11 of the gene for 48 samples (all chronic myelomonocytic leukemia, 5 essential thrombocythemia and 8 PV), and only exon 2 for the remaining 41 myeloproliferative disorder samples (primers are available on demand).
We found alterations of the NFIA gene in two patients, mentioned here as patients 1 and 2.
Patient 1, a 56-year-old woman, presented with erythrocytosis and thrombocytosis in 2003. Bone marrow examination showed megakaryocyte proliferation with large and mature morphology compatible with the diagnosis of essential thrombocythemia. She received hydroxyurea from 2005 to 2006. At treatment interruption, red cell mass increased, serum erythropoietin level became low; a JAK2 V617F mutation was detected in 25% of alleles leading to the diagnosis of PV with thrombocytosis. Resuming hydroxyurea therapy enabled stabilization of hemoglobin level and platelet count. Routine examinations and explorations never revealed signs of vascular events or hematopoietic evolution. Blood samples were collected when PV was diagnosed, 14 months away from all cytoreductive treatment. Analysis of aCGH profile of DNA extracted from peripheral white blood cells detected a deletion in the 1p31.3 region including the NFIA locus (Figures 1b and c) . It was the only visible abnormality of the profile. Sequencing of exons 2-11 of NFIA did not detect any mutation. Gene expression profiling was performed on mRNA from this case and the other myeloproliferative disorder samples using Affymetrix U133 plus 2.0 DNA microarrays, as previously described, 10 but did not detect differences in NFIA mRNA levels when compared with normal blood samples.
Patient 2, a 60-year-old man without hematological antecedent, was admitted to our Institute due to high white blood cell count with monocytosis and splenomegaly. Bone marrow examination led to the diagnosis of chronic myelomonocytic leukemia type 1. Bone marrow karyotype showed a trisomy 19 in 17 of 20 mitoses. Sequencing of NFIA, using DNA extracted from peripheral white blood cells, detected a TGT-to-CGT mutation in exon 2. This mutation should lead to a cysteine-toarginine substitution at position 102 of the protein (Figure 1d ). aCGH and DNA microarrays data were not available for this case. The patient was treated with hydroxyurea but developed acute myeloid leukemia (FAB type M5) 6 months later.
To our knowledge, this is the first report of structural alterations of the NFIA gene in hematopoietic diseases. They occurred in about 2% of our series of chronic myeloid diseases. These alterations should lead to an inactivation of the protein.
The point mutation targeted one of the conserved cysteine residues in the DNA-binding domain (Figure 1a) , probably affecting the capacity of NFIA to bind DNA and/or to dimerize. If confirmed by functional studies, it would position NFIA as a 11 The NFIC gene is already considered as a potential tumor suppressor gene. 12 The fact that the NFIAdeleted PV case had a JAK2 V617F mutation shows that several alterations may already coexist at this early stage of leukemogenesis. Deletion in a PV is coherent with the known function of NFIA in erythropoiesis. [7] [8] [9] The calculated number of NFIA gene copy suggests that the deletion was present at the heterozygous state in almost all cells or homozygous in around half the cells. The moderate JAK2 V617F allele burden suggests that the mutation may have occurred on the background of the 1p31.3 deletion. We cannot exclude that the NFIA mutation is not present in the germ line. However, NFIA haplo-insufficiency has a deleterious effect when occurring in germinal cells in the mouse. 3 Increased expression of NFIB mRNA in granulocytes has been described in PV, 13 which may suggest a compensatory or antagonist function of NFIB.
Our work suggests that NFIA could be added to the increasing list of transcription regulators whose alteration may have a function in leukemogenesis. 6 These authors contributed equally to this work.
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The 26S proteasome comprises the 19S proteasome that performs a regulatory function, and the 20S proteasome that is responsible for the enzymatic degradation of proteins. The 20S proteasome comprises a-and b-subunits that form the outer and inner rings of this complex, respectively. 1 The a-subunits form an antechamber that gives the proteasome its barrel shape and regulates the flow of substrates into the proteolytic chamber in the center of the barrel. 1 The b-subunits form the proteolytic chamber of the 20S proteasome and perform the peptidase function of the complex.
1 Bortezomib (Velcade) is an intravenous proteasome inhibitor that is approved for the treatment of multiple myeloma and mantle cell lymphoma. 2, 3 Mechanistically, Bortezomib binds the active sites of the enzymes in the b-subunits located in the proteolytic chamber of the 20S proteasome. 4 Molecules that inhibit the proteasome through a different mechanism would be useful probes to understand the activity of this enzyme complex and potentially new therapeutic agents.
5-chloro-7-iodo-quinolin-8-ol (clioquinol) (Figure 1a ) is a copper-binding halogenated 8-hydroxyquinoline that was used in the 1950s-1970s as an oral antiparasitic agent for the treatment and prevention of intestinal amebiasis, but its mechanism of action as an anti-parasitic agent was unknown. Recent studies in solid tumor cell lines have demonstrated that clioquinol, when supplemented with copper, can inhibit the
